FOLH1 and prostate cancer: Dhar’s group selected prostate-specific membrane antigen (PSMA) as a tumor target, and conjugated PSMA aptamers on the surface of cisplatin-loaded NPs prepared by poly(D,L-lactic acid-co-glycolic acid) and poly(ethylene glycol) chains to kill prostate cancer cells [96].